About
Pricing
FAQs
Providers
Trials
Blog
Back to your record
Login
Get started
Finding studies
Search
Narrow
Order
Status
Recruiting
Not yet recruiting
Active, not recruiting
Enrolling by invitation
Completed
Terminated
Phase
Early phase 1
Phase 1
Phase 1–2
Phase 2
Phase 2–3
Phase 3
Phase 4
Not applicable
Who can join
Healthy volunteers too
Searching
1–20 of 2,287
Completed
Bevacizumab in Combination With Metronomic Temozolomide for Recurrent Malignant Glioma
This is a phase II study of the combination of Avastin and metronomic temozolomide in recurrent malignant glioma patients.
NCT00501891
·
Durham, North Carolina
Recruiting
A Clinical Trial of P134 Cells in Recurrent Glioblastoma
This is an open-label, single-arm, dose-escalation and expansion Phase 1/2 clinical trial designed to evaluate the safety, tolerability and efficacy of P134 cells in patients with…
NCT07318818
·
Beijing
Completed
Tadalafil to Overcome Immunosuppression During Chemoradiotherapy for IDH-wildtype Grade III-IV Astrocytoma
Increasing preclinical and clinical data have shown that myeloid-derived suppressor cells (MDSCs) may represent a significant driver of immunosuppression in glioblastoma (GBM…
NCT04757662
·
St Louis, Missouri
Unknown
Vitamin D for Treatment of Glioblastoma Multiforme
This is non-randomized phase 2 study to assess efficacy and toxicity of long term high dose vitamin D3 given concurrently with chemo-radiotherapy (CCRT) containing temozolomide…
NCT01181193
·
Beersheba
Unknown
Immunohistochemical Assessment of Programmed Death ligand1 and LC3B in GBM
Glioblastoma(GBM) is the most common malignant primary brain tumor and has unfortunately bad prognosis .PDL(Programmed death lignad 1)1 is alignad for a protein receptor…
NCT04284306
Completed
A Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies
This is a multicenter, open label, Phase 1 dose-escalation study of DSP-7888 Dosing Emulsion administered to adult patients with advanced malignancies.
NCT02498665
·
Denver, Colorado and 7 others
Terminated
VAL-083 Phase 3 Study in Temozolomide-Avastin (Bevacizumab) Recurrent GBM
This is an adaptive design, randomized controlled, Phase 3 clinical trial in patients with glioblastoma multiforme (GBM) or gliosarcoma (GS), previously treated with surgery (if…
NCT03149575
·
Los Angeles, California and 4 others
Terminated
Gene Therapy and Chemotherapy in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma
RATIONALE: Gene therapy may improve the body's ability to fight cancer or make the cancer more sensitive to chemotherapy.
NCT00003567
·
Cleveland, Ohio
No longer available
SurVaxM Expanded Access Protocol
Data from clinical trials suggest that SurVaxM administered as a single agent, or in combination with standard glioblastoma chemotherapy treatment regimens to patients with…
NCT04802447
Recruiting
Living Well With Brain Cancer: A Group-Based Intervention to Promote Whole-Person Well-Being
The goal of this clinical trial is to learn if the newly designed group self-management program is feasible to conduct and improves mental and behavioral health outcomes compared…
NCT07628647
·
Aurora, Colorado and 1 other
Not yet recruiting
Safety And Effectiveness Of NaviFUS System With Bevacizumab In Recurrent Glioblastoma
This study will evaluate the safety and early effectiveness of the NaviFUS system with concomitant microbubble administration in conjunction with BEV in recurrent GBM patients.
NCT07274787
·
Cincinnati, Ohio
Completed
Study To Test the Safety and Efficacy of TVI-Brain-1 As A Treatment for Recurrent Grade IV Glioma
TVI-Brain-1 is an experimental treatment that takes advantage of the fact that your body can produce immune cells, called 'killer' white blood cells that have the ability to kill…
NCT01290692
·
Kansas City, Missouri and 3 others
Terminated
Tumor Resection and Gliadel® Wafers, Followed by Temodar® With Standard Radiation or GammaKnife® for New GBM
A glioblastoma (GBM) is the most common malignant primary brain tumor, yet it is not easy to control.
NCT02085304
·
Phoenix, Arizona
Unknown
FKBP51s: a New Molecular Biomarker for Glioblastoma? Pre- and Post-operative Blood Levels Evaluation of FKBP51s Protein and Correlation With MRI Phenotype
The aim of this interventional study is to investigate the correlation between Magnetic Resonance Phenotype and levels of FKBP51s protein pre and post surgery in adult patients…
NCT05793021
·
Roma
Completed
Neoadjuvant Nivolumab in Glioblastoma
Neoadjuvant nivolumab will be administered to patients with primary and recurrent glioblastoma multiforme that require surgery. Nivolumab will be continued following surgery.
NCT02550249
·
Pamplona, Navarre
Withdrawn
Effect of Timing of Tumor-Treating Fields Plus Short-Course Radiation
The purpose of the study is to assess timing of TTFields use as well as safety, feasibility and preliminary efficacy of treatment with TTFields in elderly patients with newly…
NCT04218019
·
Heidelberg
Active not recruiting
Pembrolizumab for Newly Diagnosed Glioblastoma
The study explores the addition of pembrolizumab to temozolomide-based radiotherapy in patients with newly diagnosed glioblastoma.
NCT03899857
·
Bern and 2 others
Terminated
TRC105 for Recurrent Glioblastoma
Background: \- Glioblastoma is an aggressive type of brain cancer that often resists treatment. TRC105 is an experimental drug that blocks the growth of new blood vessels.
NCT01778530
·
Bethesda, Maryland
Terminated
Boron Phenylalanine With or Without Mannitol in Treating Patients With Glioblastoma Multiforme
RATIONALE: Giving boron phenylalanine in different ways and measuring it in tissue in patients with glioblastoma multiforme may help in planning better radiation therapy, such as…
NCT01233492
·
Birmingham, England and 1 other
Recruiting
A Study of Zedoresertib (Debio 0123) in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Zedoresertib (Debio 0123) in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma
The primary purpose of the Phase 1 (Dose Escalation) of this study is to identify the dose-limiting toxicities (DLTs) of zedoresertib combined with temozolomide (TMZ) (Arm A) and…
NCT05765812
·
Chicago, Illinois and 15 others
Back
1
2
3
···
115
1 / 115
Next
Data from
ClinicalTrials.gov
Terms
